Zynerba's cannabis-based gel meets main goal in mid-stage study

(Reuters) - Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel achieved the main goal in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities.